Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)

Joan H. Schiller

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Expression of epidermal growth factor and its transmembrane receptor (EGFR) stimulates tumor growth. Matuzumab is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth, and provides a clinical benefit for some patients. The plasma half-life (6-10 days) and pharmacodynamic activity allow flexible dosing on weekly, every-2-week, and every-3-week schedules. Matuzumab has shown single-agent antitumor activity in heavily pretreated patients with a variety of tumors, with a favorable safety profile. Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab.

Original languageEnglish (US)
Pages (from-to)81-95
Number of pages15
JournalCancer Investigation
Volume26
Issue number1
DOIs
StatePublished - Jan 14 2008

Keywords

  • Anti-EGFR therapeutics
  • EGFR
  • Matuzumab
  • Pharmacodynamics
  • Pharmacokinetics
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)'. Together they form a unique fingerprint.

Cite this